Last Week in Longevity #13 - $193M raised + €2.5bn for healthcare investments
Your weekly business digest of everything that happened in longevity.
👋 Hi, I am Fabian, and welcome to my newsletter Last Week in Longevity. Every week, I track where the money, talent, and ideas are moving in the longevity business.
💸 Closed funding rounds
US$ 193M raised across 5 deals (↘️ -19% vs. US$ 239M across 6 deals last week)
Direct Longevity Interventions (Category 1)
Blueprint (Bryan Johnson) – US$ 60M | Los Angeles, USA
What they do: “Project Blueprint” lifestyle & prevention protocol being productized as a consumer platform (nutrition, sleep, exercise, monitoring).
Why it matters: If successfully standardised and scaled, structured prevention could shift large populations toward earlier, measurable healthspan gains.
Investors: long list of celebrity investors incl. Kim Kardashian, Logan Paul, Steve Aoki and many more
Valuation: unknown
Longevity-Aligned Disease Modification (Category 2)
Zag Bio – US$ 80M (Series A) | Cambridge, USA
What they do: Thymus-targeted bifunctional antibodies to induce central immune tolerance; lead in Type 1 diabetes.
Why it matters: Durable, antigen-specific tolerance could reduce lifelong autoimmune burden and complications that shorten healthspan.
Investors: co-led by Polaris and the T1D Fund; participants include Mission BioCapital, AbbVie Ventures, Lightspeed Ventures, Sanofi Ventures, KdT Ventures, Regeneron Ventures, Boxer Capital, Pear VC, among others
Valuation: unknown
Adaptam Therapeutics – €3M (pre-seed) | Barcelona/San Sebastián, Spain
What they do: Cancer immunotherapies targeting immunosuppressive myeloid cells (incl. ADCs and bispecifics).
Why it matters: Better myeloid-targeted IO could improve outcomes and tolerability in age-associated cancers.
Investors: Led by Criteria Bio Ventures (founding investor)
Valuation: unknown
Longevity Enablers (Category 3)
Curve Biosciences – US$ 40M (financing) | San Mateo, USA
What they do: “Whole-Body Intelligence” platform—tissue-anchored atlas + blood tests to anticipate and monitor chronic disease.
Why it matters: Earlier, system-level detection can personalize prevention/therapy and compress morbidity—classic Category 3 longevity enabler.
Investors: Led by Luma Group; participants include First Spark Ventures, Techas Capital, Civilization Ventures, LifeX Ventures, Incite, Mintaka VC, NZVC and others.
Valuation: unknown
Bevel – US$ 10M (Series A) | New York, USA
What they do: AI health companion that unifies wearable and habit data (sleep, fitness, nutrition) into personalized daily guidance.
Why it matters: Continuous behavioral guidance and adherence support enable earlier course-corrections and measurable risk-reduction at population scale.
Investors: General Catalyst (Series A lead)
Valuation: unknown
📰 Top longevity business news
€2.5 bn fund signals Europe’s healthcare-investment surge
What happened:
GHO Capital closed its Fund IV at over €2.5 billion, bringing its total assets under management (AUM) to around €9 billion — making it Europe’s largest healthcare-specialist private equity firm. Read more here.Why it matters:
For the longevity & health-tech sector this is a strong signal: first, large pools of capital are available specifically for healthcare/biotech/medtech in Europe, which means more investment flows into longevity-adjacent businesses. Second, the sheer size of the fund suggests investor conviction in this sector despite broader macro uncertainty. Third, having such a major fund active in Europe improves the exit/opportunity environment for startups in longevity, meaning earlier-stage companies have more realistic paths to growth or acquisition.
Biotech VC rebounds 71% in Q3 2025 to US$3.1 billion
What happened:
Venture capital investments in biotech rose ~70.9% in Q3 2025 (from US$1.8 billion in Q2 to US$3.1 billion), driven by later-stage rounds and M&A activity. Read more here.Why it matters:
From a longevity business perspective this is highly relevant: funding momentum is returning to biotech, which means more available capital and possibly better valuations for companies with credible longevity/health-span propositions. It also indicates a shift toward growth/later-stage rounds (Series D) rather than purely early-stage, which hints that investors are looking for more mature longevity propositions — meaning startups need stronger proof/pipeline to attract capital.
🗓 Events & meetups (Europe-only)
(FR) Tech for Longevity 2025 (Nov 25-26, 2025)
(ES) 4th Longevity World Forum (Feb 18-20, 2026)
(CH) SIP Longevity Retreat (Apr 20-24, 2026)
(PT) 4th Global Longevity Med Summit (May 6-7, 2026)
(DE) LIFE Summit (May 29-30, 2026)
(IE) Longevity Summit Dublin (Jun 24-26, 2026)
(NL) HLTH Europe (Jun 15-18, 2026)
(CZ) 8th World Aging & Rejuvenation Conference (Jun 18-19, 2026)
(UK) The Longevity Show (Jun 26-27, 2026)
(AT) 2nd World Congress on Future of Aging & Rejuvenation Science (Jul 20-21, 2026)
(DE) POLLY Longevity Festival (Aug 21-23, 2026)
💼 New Longevity jobs (Europe-only)
(Berlin) Longevity Coach/Medical Doctor @ Tomorrow Biostasis
(Berlin) Key Account @ Longevity Club Berlin
👉 To see the full list of all Longevity jobs, visit our Job Board.
Keep building the future of longevity - one week at a time.
Fabian
P.S. Want your open positions or events to be featured? Just send them my way by replying to this email.